SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

ATH (ATH) News

Follow ATH (ATH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ATH Asset equity Sector Markets 90 days 17 Last 83.32 Updated Oct 29, 2026, 02:44 AM UTC Open live news feed Open ATH chart & news
M Athabasca Oil Reports Quarterly Results for Period Ended September 30 The earnings summary was machine-generated from LSEG data. Figures are in Canadian dollars unless otherwise stated. EQUITY | Oct 29, 2026, 02:44 AM UTC M Cenovus to Acquire Athabasca Oil for $12 per Share The agreed $5.7 billion cash-and-share deal was announced Oct. 5, 2026, and is subject to approvals. EQUITY | Oct 28, 2026, 11:07 PM UTC L Athabasca Oil Reports Third-Quarter EPS EARNINGS | Oct 28, 2026, 11:04 PM UTC M Cenovus Energy to Acquire Athabasca Oil for Premium Cenovus Energy is paying a premium for Athabasca Oil, a price TD Cowen analyst Menno Hulshof believes is justified by "growth, resource depth and synergy potential." EQUITY | Oct 05, 2026, 02:38 PM UTC M Cenovus Buys Athabasca Oil for C$5.7 Billion Amidst Energy Supply Focus Cenovus Energy is acquiring Athabasca Oil in a C$5.7 billion deal, marking another significant consolidation in Canada's oil sands region. This move by major Canadian producers aims to secure contiguous, long-life oil as MNA | Oct 05, 2026, 12:27 PM UTC H Cenovus Energy to buy Athabasca Oil for $5.7 billion Cenovus Energy has agreed to acquire Athabasca Oil in a deal valued at $5.7 billion, including debt. Under the terms of the agreement, Cenovus will pay $12.00 per share for Athabasca. The acquisition is expected to close MNA | Oct 05, 2026, 11:47 AM UTC M Alterity Therapeutics ATH434 Slows MSA Decline by 52% in Phase 2 Trial Alterity Therapeutics reported new Phase 2 analyses for its drug ATH434, showing that a 50 mg dosage significantly slowed functional decline by approximately 52% compared to a placebo over 52 weeks, as measured by the UM EQUITY | Oct 05, 2026, 11:08 AM UTC H Cenovus to Acquire Athabasca Oil for C$5.7 Billion Cenovus Energy has agreed to acquire Athabasca Oil in a cash-and-stock deal valued at C$5.7 billion, expanding its thermal oil sands position in western Canada. EQUITY | Oct 05, 2026, 10:33 AM UTC H Athabasca Oil to be acquired by Cenovus Energy Athabasca Oil Corporation has announced an agreement to be acquired by Cenovus Energy Inc. MNA | Oct 05, 2026, 10:08 AM UTC M Union Pacific upgraded to Buy by UBS for 2027 outlook UBS upgraded Union Pacific to Buy, citing an expected 3.5% volume growth in 2027, including 6% to 7% intermodal volume growth, plus indications of a pricing tailwind from trucking into next year. EQUITY | Sep 16, 2026, 04:01 PM UTC M Athabasca Oil downgraded at BMO on premium valuation risk BMO analyst Tariq Saad downgraded Athabasca Oil’s rating to market perform from market outperform, citing that the shares are within the 10% threshold of the target. ENERGY | Sep 16, 2026, 03:00 PM UTC L Alterity Therapeutics Price Target Announced at $10.00/Share by Lake Street Ratings actions from Benzinga NEWS | Sep 15, 2026, 04:06 PM UTC L RBC Capital maintains Athabasca Oil at Sector Perform, price target C$12 RBC Capital maintained its Sector Perform rating on Athabasca Oil Corp. The firm also maintained its C$12.00 per share price target, as reported by Baystreet/TradingView News. EQUITY | Sep 10, 2026, 03:37 PM UTC L ATH: Disciplined growth, robust free cash flow, and fully funded expansions drive long-term value Focused on high-quality thermal oil and Duvernay assets, the company targets strong per-share growth, robust free cash flow, and fully funded expansions. With an 85-year reserve life, disciplined capital returns, and a p ENERGY | Sep 08, 2026, 08:19 PM UTC L Alterity Therapeutics to join Cantor Global Healthcare conference fireside chat Alterity Therapeutics said David Stamler will participate in a fireside chat at the Cantor Global Healthcare Conference 2026. EQUITY | Sep 03, 2026, 11:08 AM UTC M Burry warns of private credit shell game involving insurers Michael Burry says a new academic paper exposes a private credit and private equity “shell game” that could shift losses onto taxpayers through life insurers. EQUITY | Sep 03, 2026, 07:47 AM UTC M ATH net loss up 93% to A$23.4M; Phase 3 ATH434 on track ATH reported net loss increased 93% to A$23.4M as R&D and admin costs rose, while its Phase 3 ATH434 trial is on track. EQUITY | Aug 28, 2026, 07:02 AM UTC L Athene Holding Ltd. Declares Q3 Preferred Stock Dividends Athene declares third quarter preferred stock dividends EQUITY | Aug 03, 2026, 08:30 PM UTC